​​​​

Skip Navigation LinksDevelopment-Pipeline

IMGN_Pipeline_Photo_3.jpg 

​​Product Development Pipeline

Product Development Pipeline_v3.png
*Funded by Valor Biotherapeutics, which is a joint venture formed by ImmunGene, Inc. and Caliber Biotherapeutics, LLC. 

IGN002: 

Our lead candidate, IGN002, comprises an anti-CD20 monoclonal antibody attached to IFN through stable peptide linker system. CD20 is expressed on Non-Hodgkin lymphoma and other B cell driven hematologic malignancies. We have generated substantial preclinical data with IGN002, including data demonstrating that the targeting ability of IGN002 results in up to 100-fold higher than non-targeted IFN. Further, IGN002 also shows remarkable efficacy in rituximab resistant tumor models. These preclinical data demonstrate that IGN002 effectively targets and acts locally CD20- positive tumors. Developed by Valor Biotherapeutics, which is a joint venture formed by ImmunGene, Inc. and Caliber Biotherapeutics, LLC. 

IGN001: 

Our second candidate, IGN001, comprises an anti-Her2 monoclonal antibody attached to IFN through stable peptide linker system. Her2 is expressed on breast cancer and other malignancies. We are in early stages of generating preclinical data with IGN001. Developed by Valor Biotherapeutics, which is a joint venture formed by ImmunGene, Inc. and Caliber Biotherapeutics, LLC. 

IGN003: 

Our IGN003 candidate comprises a monoclonal antibody directed towards a well validated Multiple Myeloma target attached to IFN through stable peptide linker system. We are in early stages of generating preclinical data with IGN003. Developed by Valor Biotherapeutics, which is a joint venture formed by ImmunGene, Inc. and Caliber Biotherapeutics, LLC. 

IGN004: 

Our candidate, IGN004, comprises a monoclonal antibody against a novel tumor target genetically linked to immune effector molecule. This target is expressed on hematological malignacies, multiple solid tumors, including melanoma, and non-small cell lung cancer. Our lead drug candidate has demonstrated efficacy in high-bar animal models.

IGN005: 

Our IGN005 candidate comprises an monoclonal antibody directed towards a well validated AML target genetically linked with IFN through stable peptide linker system. This target is expressed on AML and other leukemias. We are currently evaluating the lead candidate in animal models.

IGN006: 

Our candidate, IGN006, comprises an monoclonal antibody against a target attached to IFN through stable peptide linker system. This target is expressed on multiple solid tumors. We are in early stages of generating preclinical data with IGN006.

Others:

In addition to these programs, we have developed several novel tumor specific antibodies.  Engineering of drug candidates are currently in progress.